PF-06669571 In Subjects With Idiopathic Parkinson's Disease
Status:
Completed
Trial end date:
2016-05-13
Target enrollment:
Participant gender:
Summary
This study is designed to assess safety, tolerability and pharmacokinetic data for multiple
doses of PF-06669571 in subjects with idiopathic Parkinson's disease. In addition, this study
will assess whether PF-06669571 is able to demonstrate superior efficacy compared with
placebo in the treatment of the motor symptoms of idiopathic Parkinson's disease.